D.E. Shaw & Co’s Genocea Biosciences, Inc. GNCA Stock Holding History

D.E. Shaw & Co’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,747	Closed	-$31K	–	4313
2019 Q3	$31K	Sell	10,747 -10,653	-50%	-$36.4K	﹤0.01%	3746
2019 Q2	$84K	Buy	+21,400	New	+$112K	﹤0.01%	3561
2018 Q3	–	Sell	-3,711	Closed	-$25K	–	4109
2018 Q2	$25K	Buy	3,711 +1,757	+90%	+$13.1K	﹤0.01%	3664
2018 Q1	$16K	Buy	+1,954	New	+$16.2K	﹤0.01%	3441
2015 Q4	–	Sell	-2,487	Closed	-$136K	–	4054
2015 Q3	$136K	Buy	2,487 +1,101	+79%	+$109K	﹤0.01%	3576
2015 Q2	$152K	Buy	+1,386	New	+$129K	﹤0.01%	3618

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

D.E. Shaw & Co's GNCA Position: Q4 2019 in Review

D.E. Shaw & Co sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2019, closing a stake of 10,747 shares — an estimated $31K sold.

D.E. Shaw & Co first reported a position in GNCA in Q2 2015 and held it in 6 quarters. The position peaked at $152K in Q2 2015. 34 funds tracked by Wall St. Rank hold GNCA as of Q4 2019.

D.E. Shaw & Co reported no remaining Genocea Biosciences, Inc. position as of Q4 2019 after selling out during the quarter.
D.E. Shaw & Co sold 10,747 Genocea Biosciences, Inc. shares in Q4 2019, an estimated $31K.
D.E. Shaw & Co first reported a position in Genocea Biosciences, Inc. in Q2 2015 and held it in 6 quarters.
D.E. Shaw & Co's Genocea Biosciences, Inc. position peaked at $152K in Q2 2015.
34 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2019.

Based on D.E. Shaw & Co's 13F filing for Q4 2019, filed 14 Feb 2020.